CAARUD client profiles and practices in 2012
Tendances n° 98, OFDT, 8 p.
Support centres for the reduction of drug-related harms (CAARUDs) see populations that are often fragile. The harm reduction (HR) measures undertaken aim at limiting the impact of drug use (especially viral infections), providing information on the risks related to different substances and practices and promoting access to care, social benefits and acceptable living conditions, without, however, first requiring users to stop using drugs. Subsequently, French CAARUDs mainly admit users who, although they can be followed up by French healthcare system services (whether or not specialised in addiction medicine), tend to have more uncontrolled problem use than users in general. They also tend to live in more precarious social situations.
This issue of Tendances presents the results of the 2012 “ENa-CAARUD” survey (the first three surveys took place in 2006, 2008 and 2010), which monitors the characteristics of treated drug users and help improve the responses of professionals and public authorities to the changing needs of this population.
Authors : Agnès Cadet-Taïrou, Stéphane Saïd, with Magali Martinez
Download the PDF file (1,1 Mo)
Drugs in Europe
The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national data across these themes and key harm-reduction interventions. This report is based on information provided to the EMCDDA by the EU Member States, the candidate country Türkiye, and Norway, in an annual reporting process.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format.
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.